Showing 171-180 of 354 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Building the Evidence to Address Disparities in Young children with Type 1 Diabetes: BEADY-T1D | Stanford University | Ananta Addala | Improving Lives | 01-February-2025 to 31-January-2029 | $943,983.20 |
| PREdictors for DiabetIC Ketoacidosis at Diagnosis of Type 1 Diabetes (The PREDICT study) | Rutgers, The State University of New Jersey | Chintan Dave | Cures | 01-August-2022 to 31-July-2026 | $695,404.04 |
| JDRF Cures Patient Preference Study in Type 1 Diabetes | RTI International | Kelley Myers | Transportfolio | 01-July-2023 to 31-March-2027 | $831,600.00 |
| Employing PD-L1-Modified Biomaterials to Induce Islet Allograft Tolerance Following Perihepatic Transplantation in Nonhuman Primates | Regents of the University of Minnesota | Melanie Graham | Cures | 01-April-2025 to 31-March-2027 | $918,744.88 |
| Growing Beta Cell Replacement in T1D by Tolerizing Stem Cell-Derived Islets | Regents of the University of Minnesota | Bernhard Hering | Cures | 01-August-2025 to 31-July-2027 | $688,430.02 |
| Mechanistic Etiologies Underlying the Impact of Verapamil to Preserve β Cell Function in Type 1 diabetes | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-September-2024 to 30-June-2027 | $643,946.00 |
| Hybrid Closed Loop Therapy for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study (CLVerEX) | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-April-2023 to 31-March-2026 | $1,652,469.26 |
| Preservation of iPS-derived Beta islet aggregates | Regents of the University of Minnesota | Allison Hubel | Cures | 01-May-2026 to 30-April-2028 | $599,662.15 |
| Repurposing LRRK2 inhibitors for β cell protection in T1D | Regents of the University of Michigan | Scott Soleimanpour | Cures | 01-September-2023 to 31-August-2027 | $750,000.00 |
| University of Michigan and OHSU Breakthrough T1D Cardio-Renal Center of Excellence : Accelerating Breakthrough Targeted New Therapies for Cardio-Renal Complications for People with T1D | Regents of the University of Michigan | Matthias Kretzler | Improving Lives | 01-May-2025 to 30-April-2028 | $2,842,434.27 |